💊🐕 Simparica Trio and NexGard Seizure Warnings: 2026 FDA Safety Update for Dog Owners
My friend's beagle, Walter, had his first seizure on a Thursday evening — eleven days after his monthly Simparica Trio dose. He'd never had a seizure in his six years of life. He recovered fully, but the experience sent his owner down a research spiral she hadn't expected: she found an FDA alert she'd never been shown, a label warning her vet had never mentioned, and thousands of owners online who'd experienced the same thing and were just as surprised.
She also found something reassuring: for most healthy dogs, the absolute risk is low. But "low" is not zero — and some dogs have a much higher risk than others. And with the isoxazoline class now expanding to include a once-yearly injectable (Bravecto Quantum, FDA-approved July 2025) that cannot be removed from the body after administration, the stakes of understanding this warning have gotten meaningfully higher. This is the complete 2026 guide to what the FDA warning actually says, how common seizures really are, which dogs should never take these medications, and what safer alternatives exist.
📌 Quick Answer — What You Need to Know Before Reading Further
The FDA issued a public neurologic warning in September 2018 — updated August 2021 — covering all isoxazoline-class flea and tick products: Simparica Trio, NexGard, NexGard Plus, Bravecto, Credelio, and Revolution Plus for cats. The documented reactions: muscle tremors, ataxia (loss of coordination), and seizures — including in dogs with NO prior seizure history. The FDA's position: These products are still considered safe and effective for the majority of dogs. The warning exists to inform, not to prohibit use. New in 2025: Bravecto Quantum — the first once-yearly isoxazoline injection — FDA-approved July 10, 2025. Same class warning applies. Once injected, the drug cannot be removed. Dogs who should NOT take isoxazolines: Dogs with a history of seizures, epilepsy, or other neurological disorders. If your dog seizes after a dose: Do not give another dose. Call your vet same-day. Report to the FDA.
🔬 What Is the Isoxazoline Class — And Why It Dominates the Flea and Tick Market
Isoxazolines are a class of synthetic compounds that work by blocking GABA-gated chloride channels in the nervous systems of insects and arachnids — specifically fleas and ticks. When a flea or tick feeds on a dog treated with an isoxazoline, the drug enters the parasite's system, overstimulates its nervous system, and kills it within hours. The speed and reliability of this mechanism is why isoxazolines have come to dominate the prescription flea and tick market since NexGard's approval in 2013.
The four active isoxazoline ingredients and their main products are: afoxolaner (NexGard, NexGard Plus), sarolaner (Simparica, Simparica Trio), fluralaner (Bravecto chews and the new Bravecto Quantum injection), and lotilaner (Credelio, Credelio Quattro). All four are in the same mechanistic class, all four carry the same FDA neurologic warning, and all four work systemically — meaning they circulate through your dog's bloodstream. This systemic action is the core of both their effectiveness and their risk. The drug is designed to be selectively more toxic to insects than to mammals — and for most dogs, that selectivity holds. But the GABA-gated chloride channels that isoxazolines target are not entirely absent from mammalian nervous systems. In some dogs — through mechanisms that are not yet fully understood — the drug appears to cross the blood-brain barrier at levels sufficient to cause neurological effects.
📜 The FDA Warning — Timeline and What It Actually Says
The FDA's response to isoxazoline neurological reports unfolded in stages that many pet owners are unaware of:
- September 20, 2018: The FDA issued a formal Animal Drug Safety Communication alerting pet owners and veterinarians to the potential for neurologic adverse events — specifically muscle tremors, ataxia, and seizures — associated with the isoxazoline class. The alert covered Bravecto, NexGard, Simparica, and the newly approved Credelio. The FDA stated it was working with manufacturers to update product labels.
- August 2021: The FDA updated its fact sheet for pet owners and veterinarians with clarified language, explicitly noting that seizures may occur in animals without a prior history of seizure disorder — a critical addition that changed the risk conversation for many owners.
- Ongoing post-market surveillance: The FDA's Center for Veterinary Medicine (CVM) continues to collect adverse event reports through its Safety Reporting Portal. As of the most recent analysis, thousands of neurologic adverse event reports have been filed across the class.
- Current label language (required on all isoxazoline products): Products must state that the isoxazoline class has been associated with neurologic adverse reactions including tremors, ataxia, and seizures, that these have occurred in animals without prior neurologic history, and that the product should be used with caution in animals with a history of seizures or neurologic disorders.
📊 How Common Are Seizures — The Real Numbers
This is where the data gets complicated — and where honest communication matters most. The FDA's adverse event reporting system captures voluntary reports from veterinarians and pet owners. It is not a denominator-based system: it tells you how many reports were filed, not what percentage of treated dogs experienced a problem. This means raw report counts overestimate absolute risk (not all problems are caused by the drug) and simultaneously underestimate it (most adverse events are never reported to the FDA).
The most rigorous independent analysis available is the 2020 "Project Jake Survey" study, published in the peer-reviewed journal Veterinary Medicine and Science (PMC7738705). Key findings:
- FDA adverse event reports from January 2013 to September 2017 included 32,374 reportable adverse events in dogs across the isoxazoline class.
- Of sarolaner (Simparica) adverse event reports, 20.5% involved seizures — the highest proportion of any drug in the class.
- For afoxolaner (NexGard): 6.9% of adverse event reports involved seizures.
- For fluralaner (Bravecto): 2.8% of adverse event reports involved seizures.
- The European Medicines Agency data showed 7 to 10 times higher rates of death and seizures than FDA-reported US data — suggesting substantial underreporting in the US.
💊 Product-by-Product Breakdown: 2026 Isoxazoline Landscape
Simparica Trio
Sarolaner + Moxidectin + Pyrantel · Zoetis. Covers 6 tick species including Asian longhorned tick (label expanded Nov 2024). Prevents heartworm, roundworm, hookworm. FDA-approved 2020. Highest % of seizures in AE reports among class. For dogs 8+ weeks, 2.8 lb+. Liver-flavored chew.
NexGard / NexGard Plus
Afoxolaner + (Moxidectin + Pyrantel in Plus) · Boehringer Ingelheim. NexGard: flea + tick only. NexGard Plus: adds heartworm + intestinal worm prevention. Covers 5 tick species. The original isoxazoline — on market since 2013. Beef-flavored. Same FDA neurologic class warning.
Bravecto / Bravecto Quantum
Fluralaner · Merck Animal Health. Bravecto chew: 12-week protection. Bravecto Quantum: once-yearly injection FDA-approved July 2025 — first of its kind. Critical caveat: injectable form cannot be removed from body. Caution in neurologic-risk dogs is paramount.
Credelio / Credelio Quattro
Lotilaner + (Milbemycin + Praziquantel in Quattro) · Elanco. Credelio Quattro: the only combination isoxazoline with praziquantel, directly treating tapeworms. Covers 5 tick species. Beef-flavored. Newest combination product in the class. Same FDA neurologic warning applies.
🚨 The Bravecto Quantum Problem — Why the Once-Yearly Injection Changes the Risk Equation
Bravecto Quantum's FDA approval on July 10, 2025 represents a genuine convenience advance for pet owners — one injection per year instead of twelve monthly chews is meaningfully easier to manage and reduces the risk of missed doses. But it introduces a risk calculation that does not apply to any oral isoxazoline product, and owners need to understand it explicitly before choosing this option.
🩺 The Complete Side Effect Profile — Beyond Seizures
| Side Effect | Simparica Trio (sarolaner) | NexGard Plus (afoxolaner) | Bravecto Quantum (fluralaner inj.) |
|---|---|---|---|
| Seizures / Tremors / Ataxia | FDA class warning — documented | FDA class warning — documented | FDA class warning — irreversible if occurs |
| Vomiting / Diarrhea | Most commonly reported GI AEs | Most commonly reported GI AEs | Reported; also injection site swelling |
| Lethargy / Anorexia | Reported in field studies | Reported in field studies | Reported as transient |
| Injection site reaction | N/A (oral) | N/A (oral) | Swelling — expected, usually transient |
| Safe in seizure-history dogs | Contraindicated | Contraindicated | Contraindicated — with heightened caution |
| Safe in pregnant / breeding dogs | Not evaluated — avoid | Not evaluated — avoid | Not evaluated — avoid |
| Minimum age | 8 weeks | 8 weeks | 6 months (injection) |
| Duration in body | ~30 days (oral clearance) | ~30 days (oral clearance) | 8–12 months — cannot be stopped |
| Reversible if reaction occurs | Yes — stop next dose | Yes — stop next dose | No — drug continues releasing |
🚫 Dogs Who Should Never Take Isoxazoline Products
✗ Dogs with a documented history of seizures or epilepsy
- This is the clearest contraindication. Any dog that has had a seizure — regardless of suspected cause — should not receive an isoxazoline product without explicit evaluation by a veterinary neurologist.
- The FDA label itself says "use with caution in dogs with a history of seizures or neurologic disorders." In practice, most veterinary neurologists interpret this as contraindicated.
✗ Dogs with any diagnosed neurological condition
- Dogs with idiopathic vestibular disease, degenerative myelopathy, brain tumors, or other neurologic diagnoses should not receive isoxazolines without specific neurologist guidance.
- The underlying condition may lower the threshold for drug-induced neurologic effects, and distinguishing a drug reaction from disease progression becomes much harder after the fact.
✗ Breeds with high MDR1 / ABCB1 gene mutation prevalence
- The MDR1 (multi-drug resistance 1) gene mutation — also called the ABCB1 mutation — affects the blood-brain barrier's ability to exclude certain drugs, including some antiparasiticides.
- Highly affected breeds include Collies, Shetland Sheepdogs, Australian Shepherds, Border Collies, McNabs, Silken Windhounds, and German Shepherds. Genetic testing for MDR1 status is available through Washington State University's Veterinary Clinical Pharmacology Lab.
✗ Any dog with ANY neurologic risk factor considering the injectable
- For Bravecto Quantum specifically: if there is any neurologic risk factor in the dog's history — even a single unexplained episode of wobbling or disorientation that was never formally diagnosed — the irreversible nature of the injection makes it an inappropriate first choice.
- The conventional wisdom is: try an oral isoxazoline first if you want to test tolerance, then consider the injection for subsequent years if the dog tolerates the drug without neurologic events.
✅ Safe Non-Isoxazoline Alternatives for 2026
The good news is that effective, non-isoxazoline flea and tick prevention exists. The trade-offs are real — no alternative matches the broad-spectrum convenience of Simparica Trio or NexGard Plus in a single monthly chew — but for dogs with neurologic risk factors, these alternatives provide meaningful protection:
| Product | Active Ingredient(s) | Type | Coverage | Seizure Warning? |
|---|---|---|---|---|
| Frontline Plus | Fipronil + methoprene | Topical monthly | Fleas, ticks, lice, flea eggs | No FDA neurologic warning |
| Advantage Multi | Imidacloprid + moxidectin | Topical monthly | Fleas, heartworm, roundworms, hookworms, whipworms, mange | No isoxazoline — no class warning |
| Seresto Collar | Imidacloprid + flumethrin | Collar — up to 8 months | Fleas, ticks (repels and kills) | No neurologic class warning |
| Revolution (selamectin) | Selamectin | Topical monthly | Fleas, heartworm, ear mites, sarcoptic mange — limited tick coverage | No isoxazoline class warning |
| Comfortis | Spinosad | Oral monthly | Fleas only — no tick coverage | Different drug class — no isoxazoline warning |
| Interceptor Plus | Milbemycin oxime + praziquantel | Oral monthly | Heartworm + intestinal worms — no flea/tick | Non-isoxazoline — often paired with Frontline |
🚑 What to Do If Your Dog Has a Seizure After an Isoxazoline Dose
Move furniture away from your dog to prevent injury. Do not put your hands near their mouth — dogs can bite involuntarily during a seizure. Place a folded towel under their head if possible. Most importantly: look at the clock. A seizure lasting more than 2–3 minutes is a neurological emergency. Two or more seizures within 24 hours (cluster seizures) is also an emergency. Call an emergency animal hospital immediately if either occurs.
⚠ Time the seizure — duration matters for emergency decisions.After a seizure, dogs typically enter a post-ictal phase: disorientation, temporary blindness, pacing, excessive thirst or hunger, lethargy. This is normal and usually resolves within 30 minutes to a few hours. Keep the environment calm, quiet, and cool. Contact your veterinarian the same day regardless of whether the seizure appeared to resolve — even if your dog seems fully recovered. A first seizure always warrants a neurologic workup.
✓ Same-day vet contact is essential — even if recovery seems complete.Write down: (1) the date and time you gave the dose; (2) the lot number printed on the product packaging — you will need this to file an FDA report; (3) the time the seizure started; (4) how long it lasted; (5) what the seizure looked like (full-body shaking, one-sided, paddling, staring episode only); (6) your dog's behavior in the 24 hours before the seizure. This documentation serves two purposes: it helps your vet rule out other causes, and it creates the evidentiary record needed for an FDA adverse event report.
✓ Document the lot number — it's required for the FDA adverse event report.This should go without saying, but: do not give another dose of the same product. Report the adverse event to the FDA through the Safety Reporting Portal at fda.gov/safety/medwatch or by calling 1-800-FDA-1088. You can also ask your veterinarian to file a report on your behalf through the product manufacturer — manufacturers are required to forward reports to the FDA. These reports directly feed the pharmacovigilance data that drives future label updates and regulatory decisions. Filing a report helps other dogs.
✗ Do not give another dose of the same product. Ever.A first seizure requires investigation regardless of the suspected trigger. Your vet will likely recommend blood work, urinalysis, and depending on the dog's age and presentation, possible referral for MRI or spinal fluid analysis to rule out structural brain disease, metabolic causes, or true epilepsy. Only after other causes are ruled out — and only with a complete neurologic picture — should the conversation about future parasite prevention options happen. Do not restart any isoxazoline product based on the assumption that the seizure was a one-off unless a veterinary neurologist has evaluated the case.
✓ Neurologic evaluation before any future prevention decision.❓ The Questions to Ask Your Vet Before the Next Flea and Tick Prescription
🐶 Four Questions Every Dog Owner Should Ask
- "Has my dog ever had any unexplained neurological episode — trembling, wobbling, staring spells, brief loss of consciousness?" Many owners don't connect past episodes to seizures because they weren't dramatic. A brief staring episode or isolated muscle twitch that resolved on its own may have been a focal seizure. Your vet needs this history before prescribing any isoxazoline product.
- "What is my dog's breed, and does it affect the risk calculation here?" For Collie-type breeds and herding dogs, the MDR1 mutation conversation is worth having. For any breed with known cancer or neurologic disease predispositions, the systemic nature of isoxazolines warrants a more deliberate discussion than a routine prescription might generate.
- "If we choose Bravecto Quantum for convenience, what happens if my dog has a reaction?" Your vet should walk you through the irreversibility scenario before you choose the annual injection. If they haven't, ask directly. A vet who gives a complete answer to this question — rather than a reassuring one — is giving you what you need.
- "Is a non-isoxazoline combination (like Frontline Plus plus Advantage Multi) appropriate for my dog's parasite exposure level?" Tick exposure risk varies enormously by geography and lifestyle. A dog who hikes in wooded areas in the Northeast (high Lyme disease risk) has a very different tick risk profile than a city dog who mostly walks on pavement. If your dog's actual tick exposure is low, the convenience advantage of isoxazolines over non-isoxazoline combinations diminishes — and the risk calculation changes.
❓ Frequently Asked Questions
Question: My dog has been on Simparica Trio for two years with no problems. Should I switch?
Answer: Not necessarily — and not based on this article alone. A dog that has tolerated two years of monthly isoxazoline use without neurological events has demonstrated individual tolerance. The FDA warning describes a class-level risk, not a certainty for every dog. If your dog has no neurological history and has been tolerating the medication well, the risk-benefit calculation may continue to favor staying the course — especially if you live in a high-tick-density area where protection matters. The important thing is that this conversation happens with your vet as an informed decision, not as a reflex. If your dog has any new neurological symptoms — even mild ones — that's when reevaluation is warranted.
Question: Can I give Benadryl or another antihistamine to prevent a reaction to isoxazolines?
Answer: No. Antihistamines do not prevent isoxazoline-induced neurological reactions. The mechanism by which isoxazolines cause neurologic effects — if and when they do — involves GABA-gated chloride channels in the nervous system, not histamine pathways. There is no pre-treatment that reliably prevents a neurologic reaction. The only prevention is avoiding the drug class in dogs with neurologic risk factors, starting with the lowest-risk oral product rather than the long-acting injectable, and monitoring closely after the first few doses.
Question: Are there any natural or herbal alternatives to isoxazoline flea and tick prevention?
Answer: Some herbal products (essential oil-based repellents, neem, cedar oil) are marketed as flea and tick preventives. None has demonstrated efficacy comparable to pharmaceutical options in rigorous clinical trials. More importantly, none provides heartworm prevention — which is not optional in most parts of the US. For a dog with a genuine seizure disorder who needs tick and heartworm protection, the appropriate path is a non-isoxazoline pharmaceutical option (such as Advantage Multi for heartworm plus Frontline for ticks) rather than herbal products. Discuss this specifically with your vet based on your dog's disease risk and geographic location.
Question: Is the seizure risk higher with Simparica Trio than with NexGard?
Answer: The adverse event report data — from a 2020 peer-reviewed study analyzing FDA and EMA reports — showed that sarolaner (Simparica) had a higher proportion of seizure reports within its total adverse event reports (20.5%) compared to afoxolaner (NexGard, 6.9%). However, this is adverse event report data, not population-level incidence data. The differences may reflect differences in reporting patterns, differences in the treated population, or true pharmacological differences between the molecules. The FDA does not rank these products against each other for seizure risk and applies the same class-level warning to all of them. It would be inappropriate to conclude from this data that NexGard is "safe for seizure-prone dogs" while Simparica is not — both carry the same contraindication for dogs with seizure history.
Question: My dog is a Collie. Is isoxazoline safe with the MDR1 mutation?
Answer: Clinical trials for Simparica Trio, NexGard Plus, and Credelio Quattro all demonstrated safety in MDR1-mutant dogs at label doses. The label for each of these products specifically states it has been tested and found safe in MDR1-affected dogs. However, the MDR1 mutation affects drug transport across the blood-brain barrier, and individual dogs may have additional genetic variants that compound the effect. Cornell University's Riney Canine Health Center recommends disclosing the MDR1 status to your vet before any prescription drug is given, and genetic testing is available through Washington State University's Veterinary Clinical Pharmacology Lab if your dog's MDR1 status is unknown. For a confirmed MDR1-mutant Collie with a seizure history, a non-isoxazoline approach is the most conservative choice.
Medication Dates · Lot Numbers · Reaction History · Vet Records
If your dog has a reaction to a flea and tick medication, the lot number and exact date of administration are the first things your vet and the FDA need. Store every dose date, product lot number, and any observed reactions in Patify so this information is always available — especially in an emergency when you're not thinking clearly.
Download Patify📚 Key References and Further Reading
- FDA CVM Animal Drug Safety Communication — "FDA Alerts Pet Owners and Veterinarians About Potential for Neurologic Adverse Events Associated with Certain Flea and Tick Products," September 20, 2018 (fda.gov/animal-veterinary/cvm-updates)
- FDA CVM Fact Sheet — "Potential Adverse Events Associated with Isoxazoline Flea and Tick Products," updated August 2021 (fda.gov)
- FDA DailyMed — Simparica Trio (sarolaner, moxidectin, pyrantel) full prescribing information including adverse reactions (dailymed.nlm.nih.gov)
- Sherr DL, Grigg ME. "Survey of canine use and safety of isoxazoline parasiticides" — Veterinary Medicine and Science, Wiley, 2020 (PMC7738705) — Project Jake Survey: 32,374 FDA adverse event reports analyzed
- FDA — "FDA Approves Simparica Trio, a Combination Drug for Heartworm and Other Parasites" (fda.gov/animal-veterinary/cvm-updates)
- Merck Animal Health — "FDA Approves BRAVECTO QUANTUM (fluralaner for extended-release injectable suspension)," July 10, 2025 (merck-animal-health.com)
- Merck Animal Health press release — Bravecto Quantum expanded label (Asian longhorned tick + Gulf Coast tick 12 months), March 2026 (businesswire.com)
- AVMA — "Four flea, tick products linked to seizures, ataxia" (avma.org)
- Merck Veterinary Manual — "Isoxazoline Toxicosis in Animals" (merckvetmanual.com, updated 2026)
- Cornell University College of Veterinary Medicine — "Flea and tick prevention" (vet.cornell.edu)
- GoodRx Pet Health — "Bravecto Quantum for Dogs: Uses, Dosage, Side Effects" (goodrx.com, July 2025)
- Today's Veterinary Practice — "What's New With Parasiticides for Dogs and Cats" (todaysveterinarypractice.com, October 2025)
- Washington State University Veterinary Clinical Pharmacology Lab — MDR1 genetic testing program
Medical Disclaimer: This article provides a researched overview of FDA safety communications and peer-reviewed data regarding isoxazoline-class flea and tick medications as of May 2026. It does not constitute veterinary medical advice. Never stop or change a prescribed medication without consulting your dog's veterinarian. If your dog experiences a seizure or other neurologic event, seek emergency veterinary care immediately and report the event to the FDA.
